Peter Way Associates is the only known provider of the price range forecasts of widely-held, actively traded stocks derived from the hedging activities of market-making [MM] firms as they balance big-$-fund sellers and buyers in large block trades. The price ranges offer explicit downside exposure forecasts not commonly found in publicly published investment analyses.
This is all forward-looking data, based on what the MMs will pay for protection against coming unwanted price change while temporarily committed firm capital is exposed to market risks. It is available by modest subscription cost at blockdesk.com.
The behavioral analysis involved has been performed daily since Y2K, now on over 3,000 stocks, ETFs, and market indexes. That has built an actuarial history of how market prices have subsequently behaved following several million price range forecasts, issue by issue.
That data provides a qualitative backdrop to current forecasts in terms of odds of profitable positions, size of prospective gains, credibility of forecasts, and worst-case price drawdown exposure experiences.
Peter F. Way is a veteran Chartered Financial Analyst, having taken and passed the CFA Institute’s required 3 examinations in the first years they were given, 40+ years ago.
Armed with BS in Economics from the Wharton School and an MBA degree from Harvard Business School, he has managed staffs of dozens of Investment Researchers and Quantitative Analysts for the nation’s largest bank, arbitraged index options for NYSE Specialists, and managed portfolios of hundred-million-dollar equity investments for Fortune 100 corporate pension funds and non-profit endowments.
He has been elected President of professional Investment Analyst Societies in San Diego and New York City and has served on the editorial boards of the Financial Analysts Journal and the CFA Digest. He has spoken at numerous schools and professional meetings.
Founder of Old School Value (www.oldschoolvalue.com).
Fundamental Stock Analyzer & Valuation Tool for Value Investors to Save Time & Make Money
- Are you spending a lot of time manually gathering and inputting data into spreadsheets?
- Are you finding it difficult to keep up to date with fundamental company valuations?
- Do you need a way to quickly check whether a company is worth investigating?
- Do you want to know what a company is worth quickly?
The Old School Value Stock Analysis Software is a fundamental analysis and valuation tool that works for you.
Save hours each day by automatically retrieving and crunching the financials for thousands of companies.
Keep up to date easily and find more opportunities by analyzing companies faster and use the 5 valuation models to cross check whether the stock price is an attractive entry price or time to get out.
Learn more at http://try.oldschoolvalue.com/stock-analyzer/
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
Hilltop Warrior has been an investor/speculator for three decades. He writes about and trades options on the broad market, gold and silver, commodities and fixed income products and once in a while will take a stab at purchasing the odd small cap.
He spent several years as a broker at a major Canadian Brokerage before coming to his senses and realizing he ain't no salesman.
I'm an old school engineer, been active in the market since the 1980s. I have nothing to sell here, just looking to get feedback on ideas... I analyze companies using same techniques I learned for other engineering systems - look at the best tradeoffs of performance, reliability, and costs for a given environment. I do have a bias that a dollar put into my pocket is worth a lot more than than a dollar sitting in someone else's spread sheet.
A graduate of both Harvard Law School and Harvard Business School, George Putnam, III first became involved with distressed securities as a lawyer in the late 1970s. Seeing the inefficient niche that bankruptcies and turnarounds were presented and researched, he founded New Generation Research, Inc. and began publishing The Turnaround Letter in 1986.
Since then he has frequently been quoted in Barron's, The Wall Street Journal, New York Times, USA Today and other financial publications. In 1990, he was named investment advisor of the year by USA Today. In addition to his responsibilities at New Generation Research, Inc., Mr. Putnam also serves as a trustee for The Putnam Companies, a mutual fund group with over $100 billion in assets.
James Hill is a clinical assistant professor of radiology at the University of Southern California Medical School, and a patent lawyer and partner at McDermott Will & Emery.
Although he relies on publicly available information and makes reasonable efforts to confirm its accuracy, all comments made in his blog posts and articles should be considered only opinion.
Nothing in these posts or articles constitutes legal, medical, or investment advice. Always do your own due diligence and confirm all information yourself.
John Petersen is executive vice president and chief financial officer of ePower Engine Systems, Inc., a company that has developed, built and demonstrated an engine-dominant diesel-electric hybrid drivetrain for long-haul heavy trucks that promises fuel savings of 25 to 35 percent depending on terrain and payload.
John is a lawyer and accountant with over three decades of corporate finance, due diligence, M&A advisory and related legal services for manufacturers, innovators and investors in the energy storage and renewable energy sectors.
Over the last eight years John has earned a global following for his articles on the energy storage and alternative energy sectors. He has contributed to AltEnergyStocks, Seeking Alpha, The Street, NASDAQ.com and Batteries International Magazine. He currently works as a senior editor at InvestorIntel.
John is a 1979 graduate of the Notre Dame Law School and a 1976 graduate of the W.P. Carey School of Business at Arizona State University. He was admitted to the bar in 1980 and licensed to practice as a CPA in 1981. John’s diverse experience in corporate finance, natural resource development and energy storage give him a unique and sometimes unsettling perspective on the technical, economic and supply chain challenges of the battery industry.
I am a lawyer and assistant professor living in New York. My work focuses on the intersection of energy policy and the economic feasibility of energy pathways. From a financial perspective I cover a variety of energy companies ranging from renewable energy to fossil fuels. In addition to Seeking Alpha, my articles on renewable energy have been published by media sites including US News & World Report, Newsweek, The Huffington Post, and IFL Science.
While I discuss legal issues relating to these companies on occasion, my articles do not provide legal advice and nothing that I write on Seeking Alpha should be considered as such.
Michael Murphy grew up in Newark, Delaware, which a sign at the city limits proclaimed: “The Educatoinal Center of the State.” After graduating from the public schools he earned an A.B. cum laude from Harvard College and began working as a COBOL mainframe programmer on an IBM 1401 in the mid-1960s. Lured to California by the Summer of Love and better music than American Bandstand in nearby Philadelphia, he became a systems analyst and programmer for American Express, assigned to help integrate their newly-acquired San Francisco investment operations with the parent company's systems in New York. As that project ended early in 1970, a fortuitous opportunity to make a career change to Security Analyst opened up, and he leaped at the chance. His first recommendation was to sell Memorex at $172 at the very bottom of the 1969-1970 bear market. During the subsequent two-year market rally, Memorex went to $2 a share, thus convincing him that it is indeed a market of stocks rather than a stock market.
He earned his Chartered Financial Analyst (CFA) designation in 1975, the same year The Capital Group/American Funds acquired the American Express mutual fund group. He commuted to Capital in Los Angeles for over five years, getting on a first-name basis with many flight attendants. After the introduction of the IBM PC in April 1981, he left Capital to found the California Technology Stock Letter. In 1997 he also became the founding editor of Technology Investing, which acquired CTSL in 2003 and changed its name to New World Investor in 2007.
In the 1970s he invented and patented a stock value calculator, and in the 1980s he served as the CEO of two software companies. In 1997 he authored the business best-seller Every Investor's Guide to High-Tech Stocks and Mutual Funds, and he has a forthcoming book on investing in a hyperinflation. In addition to investing, his interests include a biodynamic, organic permaculture farm to raise rare-breed animals, heritage seed crops and children. For many years he held the Class I/E record for electric cars at the Bonneville Salt Flats, and in 2001 he narrowly missed the world record for electric hydroplanes. He expects to go back to Bonneville in 2019 to reclaim the electric car record with his then-16 year old daughter driving. You are all invited to watch or help out.
KLLJ is a private investor focusing on small cap stocks in biotechnology, emerging markets and renewable energy. I have been an active investor for 15 years and focus on picking stocks with tremendous upside. I enjoy sharing my thoughts in forums such as Seeking Alpha to help with my own due diligence process. I'm a critical thinker who appreciated constructive feedback to my investing ideas. I am not a short-term or momentum trader and like to think my strength is in picking good stocks with 10X potential returns. I don't believe in relying on Wall Street coverage of companies because of the inherent conflicts of interest (known or unknown.) We are in the market to make money and it is up to you, the individual retail investor to perform your own analysis for investment decisions if you want to win in the market. My analysis and viewpoints are not investment advice and you should always perform your own due diligence.
The Burrill Report is written for everyone who wants to understand how biotechnology operates as a business. Each month the publication focuses on the health of the industry and the strategies that will be needed to be successful. It provides actionable market intelligence on the latest global developments and trends in the life sciences industry. Available monthly, subscribers also benefit from monthly and quarterly market financial and business statistics on:
- Public companies
- venture financings
- Project Runway – Follow the global life sciences companies filing for and completing their IPOs – and their post market performances
- Clinical Trials successes and failures
- M&A and Partnering deals
- Periodic country features on Canada, Europe and emerging countries such as China & India.
In addition, BR provides in-depth coverage on specific sectors of life sciences including: Personalized Medicine; Diagnostics, Medical Devices and Biogreentech (Ag-Bio and Biofuels/Bioenergy). Through weekly Burrill Indices, the progress and prospects of biotech companies by size, from small through to blue-chip are also tracked.
Visit: The Burrill Report to obtain your sample issue (http://www.burrillreport.com/)
I hold degrees in Biochemistry and Business from NC State University in the heart of RTP, NC. My work experience has been in Microbiology and Pharmacy. I have experience with FDA decisions and Clinical Trials. I seek bargains and low prices, and follow Warren Buffett's principles. At the same time I am my own investor and don't always follow the same rules as everyone else. I am not opposed to Shorting Stocks and you should learn the importance of a short in the trading BioPharma Market.
See Seeking Alpha's policy on anonymous authors: http://seekingalpha.com/article/69847-seeking-alpha-policy-on-anonymous-authorship
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
I'm Ruthanne Williams Roussel, a reformed sell-side analyst who has covered the obesity space for several years. Unlike anyone else I've met who covers these companies for the big banks, I am among the target market for most of these products, which allows me to bring a consumer's perspective. In a past life, before the Asian/Russian currency crisis of 1998, I was an emerging markets specialist. Since then, I've been drawn to the closest things I can find: special situations and small-cap stocks.
Rocky spent time with Pfizer Global Research and Development and with Esperion Therapeutics before attending Columbia University to pursue a Ph.D. in organic chemistry. At Pfizer, Rocky worked in the Chemical Research and Development department working on early scale-up of potential drug molecule syntheses. At Esperion, he synthesized small peptide therapies for the treatment of atherosclerosis.
Rocky went on to receive his Ph.D. in organic chemistry from Columbia University. His thesis topic involved the development of several novel synthetic methodologies. He is currently a consultant in New York City.
“Development of a Formal [4+1] Cycloaddition: Pd(OAc)2-Catalyzed Intramolecular Cyclopropanation of 1,3-Dienyl β-Keto Esters and MgI2-Promoted Vinylcyclopropane-Cyclopentene Rearrangement”, Coscia, R. W.; Lambert, T. L. Journal of the American Chemical Society, 2009, 131, 2496-2498.
Follow me on Twitter: RockyBIP.
Disclaimer: I make every reasonable effort to make sure all data I present is factual. It is your responsibility to verify any data presented before making an investment decision. I generally do not include references to the data I present but I will provide them by request. Occasionally, errors in articles are caught after publication on Seeking Alpha and there's very little I can do to correct them in a timely manner. To see the most updated version of any article in the exact form I wished it to be presented please visit my website (www.biotechinvestmentparadigm.com).
Eamon Keane has an undergraduate degree in Mechanical Engineering and a master's degree in Energy Systems, graduating both with first class honours. He has received the Institute of Mechanical Engineers Best Student Certificate, a Veolia Environment research scholarship and two IBM PhD fellowships.
My undergraduate thesis looked at whether aluminium alloys would be a useful energy vector for in-vehicle hydrogen production (no). My master's degree thesis explored the effect high levels of wind generation would have on the economics of Combined Heat and Power (significant negative impact).
I'm interested in all things energy related, in particular oil, rare earth elements and electric vehicles.
Rich Steffens has grown up in New Jersey, is a successful businessman, and follows social media trends amongst life science and biotech companies. His family is deeply influenced by the ill effects of diabetes, and is a kidney donor to his older sister. His area of interests also includes cancer immunotherapy, which he started writing about in 2008. Rich jokes that he is one of the world's slowest marathon runners, and he runs with MSKCCs Fred's Team to support cancer research, raising over $20,000 in ten years to support MSKCCs efforts.
Rich states- I am not qualified to offer investment or medical advice, and make no claims that I am an expert in these areas. I seek to share and learn.
Mr. Becker has more than 15-years of experience as a serial entrepreneur, C-level industry executive, drug developer, Wall Street securities analyst and registered financial advisor. He is also an online communications pioneer, popular blogger, and a sought-after speaker at industry events.
Before establishing MD Becker Partners LLC (www.mdbpartners.com) in 2008, he served as president, chief executive officer, and member of the Board of Directors for several publicly-traded biotechnology companies including commercial-stage Cytogen Corporation (acquired by EUSA Pharma) and development-stage VioQuest Pharmaceuticals, Inc.
While at Cytogen, Mr. Becker held positions of increasing responsibility, including Vice President of Business Development, Industry Relations, Investor Relations and Chief Executive Officer of AxCell Biosciences, a subsidiary of Cytogen focused on signal transduction pathways. During his tenure at Cytogen, Mr. Becker raised in excess of $130 million in new capital through both public offerings and private placements and in-licensed Caphosol(c), a topical oral agent and prescription medical device for the treatment of oral mucositis and xerostomia.
Prior to joining Cytogen, Mr. Becker was with Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where he held senior positions as a biotechnology securities analyst, financial advisor and portfolio manager. He was also the founder and Executive Editor of Beck on Biotech, a monthly biotechnology investment newsletter published from July 1998 through March 2001. Mr. Becker was previously with Kidder, Peabody & Co., Gruntal & Co., L.L.C., and Kemper Securities. He has previously held the following financial licenses: Series 7 (Registered Representative), Series 16 (Securities Analyst), Series 63 (Uniform Securities Agent) and Series 65 (Registered Investment Advisor).
Mr. Becker plays an active leadership role as an advocate for the biotechnology industry. He is past Chairman and member of the board of trustees with BioNJ, which is New Jersey's trade association for biotechnology companies, and is currently a member of BioNJ, Pennsylvania Bio, the New Jersey Technology Council (NJTC), and the Pharmaceutical Consulting Consortium, Inc. (PCCI). Mr. Becker placed as a biotechnology/life sciences finalist for the Ernst & Young Entrepreneur of the Year award in both 2004 and 2005 and was listed in BusinessWeek's "CEO's 40 and Under" article in December 2006. He attended DePaul University in Chicago, Illinois.
MD Becker Partners newsletter site can be found at: http://lifesciencedigest.com
I have extensive knowledge on drug discovery, also I am interested in fundamental analysis of biotech/pharma stocks.
See Seeking Alpha's policy on anonymous authors: http://seekingalpha.com/article/69847-seeking-alpha-policy-on-anonymous-authorship
Zacks Small-Cap Research coverage specifically looks to focus on small- and micro-cap companies that are under-followed or under-valued by Wall Street. Our analysts seek to indentify and report on these companies, bringing to investors a unique opportunity to invest in small-cap ideas believed to be well-positioned for future growth. Our goal is to produce high quality research for the small cap portfolio.
Grant Zeng: Grant has 8 plus years professional experience in equity research and analysis. He is currently a senior biotech analyst with Zacks Investment Research Inc. since March 2006. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science. Grant obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China. Grant is a Chartered Financial Analyst (CFA) charter holder, and series 7, 86/87 licensed.
Ken Nagy: Ken has been a Senior Research Analyst in the Technology Sector at Zacks Investment Research since he first joined the firm in 2003. Ken’s prior analyst positions include Scudder Funds, Investor’s Bank and Trust, and Westrock Advisors. Mr. Nagy has been quoted in such publications as Forbes, Bloomberg, Reuters, CNN Money and Yahoo Finance. Ken’s education includes a Masters degree in Finance from Northeastern University, and a Bachelor of Arts in Accounting from Assumption College. He holds the Chartered Financial Analyst (CFA) designation and is a member of the Boston Security Analysts Society and the CFA Institute.
Brian Marckx, CFA is the Senior Medical Device / Diagnostics Analyst with Zacks Investment Research. I cover small and micro-cap medical device and diagnostic companies. Focus is development-stage companies with novel and emerging technologies as well as already established names still flying under the radar.
Prior to joining Zacks, Brian worked as a high-yield bond analyst on Wachovia Securities’ institutional trading desks where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Brian has covered the medical device, pharmaceutical and biotechnology industries since joining Zacks.
Brian has been quoted in numerous publications including The Wall Street Journal, Barron's, Bloomberg-Businessweek and Kiplinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. Brian graduated with a B.S. in Finance from St. John Fisher College and received his MBA from Wake Forest University. Brian is also a Chartered Financial Analyst charterholder.
John received his PhD in chemistry in the research group of Nobel Laureate Donald Cram in 1987 and his MBA from the Anderson School of Management at UCLA in 2009. His research career spans 16 years performing drug discovery research in metabolic diseases, cancer, HIV infection, antibacterials, and Alzheimer's disease. In 2011 John joined Sagient Research Systems as a Biotechnology Analyst. In 2013 he joined Zack's Small Cap Research as an Analyst.
On Twitter: @johntuckerphd
As John is neither licensed nor qualified to act as an investment advisor, his articles are written for discussion purposes only and should not be construed as investment advice. He makes a reasonable effort to avoid misstatements of fact, but advises all investors to consult primary sources prior to making an investment.
I am an individual investor that eagerly digs into a company's financial data to see what I can learn about it. Deciphering the mysteries of financial reports has been a long-term quest that began when a pre-Internet mailman unexpectedly left some company's formal report at my door. Over time, I synthesized various approaches for fundamental analysis into one ever-evolving methodology to assess performance and value.
The Gauging Corporate Financial Results blog describes the analyses I perform and the methodology itself. Writing about these efforts helps focus my thoughts. I share them with the hope I might be helping other investors. I know I benefit from reader feedback.